ATE256698T1 - Biologisch aktive peptide und ihre zubereitungen und verwendungen - Google Patents

Biologisch aktive peptide und ihre zubereitungen und verwendungen

Info

Publication number: ATE256698T1
Authority: AT; Austria
Prior art keywords: preparations; biologically active; active peptides; derivatives; geodiamolide
Prior art date: 1995-04-20

Application number

AT96910116T

Other languages

English (en)

Inventor

Raymond Andersen

Chemistry

John Coleman

Silva Dilip De

Fangming Kong

Edward Piers

Debra Wallace

Michel Roberge

Biochemistry

Theresa Allen

Original Assignee

Univ British Columbia

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-20

Filing date

1996-04-22

Publication date

2004-01-15

1996-04-22 Application filed by Univ British Columbia filed Critical Univ British Columbia

2004-01-15 Application granted granted Critical

2004-01-15 Publication of ATE256698T1 publication Critical patent/ATE256698T1/de

Links

238000002360 preparation method Methods 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1
JGALXBSQYGEYPE-BFGKGAQZSA-N (3s,6r,9s,12s,16r,18s)-6-[(4-hydroxy-3-iodophenyl)methyl]-3,7,9,12,16,18-hexamethyl-14-methylidene-1-oxa-4,7,10-triazacyclooctadecane-2,5,8,11,15-pentone Chemical compound O=C1N[C@@H](C)C(=O)O[C@@H](C)C[C@@H](C)C(=O)C(=C)C[C@H](C)C(=O)N[C@@H](C)C(=O)N(C)[C@@H]1CC1=CC=C(O)C(I)=C1 JGALXBSQYGEYPE-BFGKGAQZSA-N 0.000 abstract 1
KQODQNJLJQHFQV-MKWZWQCGSA-N (e,4s)-4-[[(2s)-3,3-dimethyl-2-[[(2s)-3-methyl-2-(methylamino)-3-(1-methylindol-3-yl)butanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid Chemical class C1=CC=C2C(C(C)(C)[C@@H](C(=O)N[C@H](C(=O)N(C)[C@H](\C=C(/C)C(O)=O)C(C)C)C(C)(C)C)NC)=CN(C)C2=C1 KQODQNJLJQHFQV-MKWZWQCGSA-N 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
230000002927 anti-mitotic effect Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
JGALXBSQYGEYPE-UHFFFAOYSA-N geodiamolide G Natural products O=C1NC(C)C(=O)OC(C)CC(C)C(=O)C(=C)CC(C)C(=O)NC(C)C(=O)N(C)C1CC1=CC=C(O)C(I)=C1 JGALXBSQYGEYPE-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Crystallography & Structural Chemistry (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

AT96910116T 1995-04-20 1996-04-22 Biologisch aktive peptide und ihre zubereitungen und verwendungen ATE256698T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9508195.6A GB9508195D0 (en)	1995-04-20	1995-04-20	Novel biologically active compounds and compositions,their use and derivation
PCT/GB1996/000942 WO1996033211A1 (en)	1995-04-20	1996-04-22	Biologically active peptides and compositions, their use

Publications (1)

Publication Number	Publication Date
ATE256698T1 true ATE256698T1 (de)	2004-01-15

Family

ID=10773352

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96910116T ATE256698T1 (de)	1995-04-20	1996-04-22	Biologisch aktive peptide und ihre zubereitungen und verwendungen

Country Status (12)

Country	Link
US (4)	US6153590A (de)
EP (1)	EP0839154B1 (de)
JP (2)	JP4008493B2 (de)
AT (1)	ATE256698T1 (de)
AU (1)	AU5341696A (de)
CA (1)	CA2220021C (de)
DE (1)	DE69631141T2 (de)
DK (1)	DK0839154T3 (de)
ES (1)	ES2213173T3 (de)
GB (1)	GB9508195D0 (de)
PT (1)	PT839154E (de)
WO (1)	WO1996033211A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2225325A1 (en) *	1997-12-19	1999-06-19	The University Of British Columbia	Hemiasterlin analogs
EP1159273A1 (de)	1999-03-02	2001-12-05	Boehringer Ingelheim Pharmaceuticals Inc.	Verbindungen, verwendbar als reversible inhibitoren von cathepsin s
MY164077A (en) *	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
US6420364B1 (en)	1999-09-13	2002-07-16	Boehringer Ingelheim Pharmaceuticals, Inc.	Compound useful as reversible inhibitors of cysteine proteases
MXPA02011319A (es) *	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.
BR0115162A (pt) *	2000-11-06	2003-10-21	Pharma Mar Sa	Tratamentos antitumorais eficazes
GB0202544D0 (en) *	2002-02-04	2002-03-20	Pharma Mar Sa	The synthesis of naturally occuring ecteinascidins and related compounds
KR101208266B1 (ko) *	2002-03-22	2012-12-05	에자이 알앤드디 매니지먼트 가부시키가이샤	헤미아스텔린 유도체 및 이의 용도
US7064211B2 (en) *	2002-03-22	2006-06-20	Eisai Co., Ltd.	Hemiasterlin derivatives and uses thereof
MXPA05002874A (es)	2002-09-20	2005-05-27	Wyeth Corp	Procedimiento para la sintesis de intermediarios utiles para la sintesis de inhibidores de tubulina.
WO2004026293A2 (en) *	2002-09-20	2004-04-01	Wyeth Holdings Corporation	Hemiasterlin derivatives for treating resistant tumors
WO2004042350A2 (en) *	2002-10-30	2004-05-21	Merck & Co., Inc.	Using amines or amino acids as mobile phase modifiers in chromatography
AU2003295808A1 (en) *	2002-11-21	2004-06-18	Wyeth	Hemiasterlin affinity probes and their uses
GB0312407D0 (en) *	2003-05-29	2003-07-02	Pharma Mar Sau	Treatment
US7390910B2 (en) *	2003-08-08	2008-06-24	Wyeth	Compounds for treating tumors
GB0324201D0 (en) *	2003-10-15	2003-11-19	Pharma Mar Sau	Improved antitumoral combinations
HRP20080598T3 (en) *	2003-11-13	2009-01-31	Pharma Mar	Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
AU2004291037A1 (en) *	2003-11-14	2005-06-02	Pharma Mar, S.A.	Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) *	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
WO2006005602A2 (en) *	2004-07-09	2006-01-19	Pharma Mar, S.A.	Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
AU2005288696A1 (en) *	2004-09-28	2006-04-06	Pharma Mar S.A., Sociedad Unipersonal	Ecteinascidin compounds as anti -inflammatory agents
EP1827500B1 (de) *	2004-10-26	2009-05-06	Pharma Mar S.A., Sociedad Unipersonal	Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743
ATE368461T1 (de)	2004-10-29	2007-08-15	Pharma Mar Sa	Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
JP2008522624A (ja) *	2004-12-09	2008-07-03	エーザイ・アール・アンド・ディー・マネジメント株式会社	ヘミアスタリン（ｈｅｍｉａｓｔｅｒｌｉｎ）アナログを使用する癌治療におけるチューブリンのアイソタイプのスクリーニング
KR20080006012A (ko) *	2005-05-05	2008-01-15	에자이 가부시키가이샤	(2ｅ,4ｓ)-4-[(ｎ-｛[(2ｒ)-1-이소프로필피페리딘-2-일]-카르보닐｝-3-메틸-ｌ-발릴)(메틸)아미노]-2,5-디메틸헥스-2-엔산의 비용매화된 결정성 형태 및 호스트-게스트 용매화된결정성 형태, 및 그의 약제학적 용도
GB0522082D0 (en) *	2005-10-31	2005-12-07	Pharma Mar Sa	Formulations
EP2118127A4 (de) *	2007-01-31	2010-12-01	Affymax Inc	Linker auf stickstoffbasis zur bindung modifizierender gruppen an polypeptide und andere makromoleküle
US20100267732A1 (en) *	2007-10-19	2010-10-21	Pharma Mar, S.A.	Prognostic Molecular Markers for ET-743 Treatment
KR101614723B1 (ko)	2008-01-11	2016-04-22	알바니 몰레큘라 리써치, 인크.	Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌
WO2011003007A1 (en)	2009-07-01	2011-01-06	Albany Molecular Research, Inc.	Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US8618299B2 (en)	2009-07-01	2013-12-31	Albany Molecular Research, Inc.	Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
JP2012532144A (ja)	2009-07-01	2012-12-13	アルバニーモレキュラーリサーチ，インコーポレイテッド	アジノン置換アゼピノ［ｂ］インドールおよびピリド−ピロロ−アゼピンｍｃｈ−１拮抗薬、ならびにその作製方法および使用
US9073925B2 (en)	2009-07-01	2015-07-07	Albany Molecular Research, Inc.	Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8993765B2 (en)	2010-12-21	2015-03-31	Albany Molecular Research, Inc.	Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en)	2010-12-21	2014-04-15	Albany Molecular Research, Inc.	Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
CN103570603A (zh) *	2012-07-19	2014-02-12	杭州中肽生化有限公司	哈米特林的一种合成新方法
HK1220626A1 (zh)	2013-03-15	2017-05-12	The Centre For Drug Research And Development	具细胞毒性和抗有丝分裂的化合物以及其使用方法
WO2015095953A1 (en)	2013-12-27	2015-07-02	The Centre For Drug Research And Development	Sulfonamide-containing linkage systems for drug conjugates
BR112016015105A8 (pt)	2013-12-27	2018-04-24	Var2 Pharmaceuticals Aps	conjugados var2csa-droga
ES2905569T3 (es)	2014-09-17	2022-04-11	Zymeworks Inc	Compuestos citotóxicos y antimitóticos y métodos para utilizarlos
CA3001065A1 (en)	2015-10-14	2017-04-20	Xiaoxi WEI	Compositions and methods for reducing ice crystal formation
US10517958B2 (en)	2016-10-04	2019-12-31	Zymeworks Inc.	Compositions and methods for the treatment of platinum-drug resistant cancer
EP4321523A3 (de)	2017-08-10	2024-04-24	Sumitomo Pharma Co., Ltd.	Hemiasterlinderivate und antikörper-wirkstoff-konjugate damit
PL3666787T3 (pl)	2017-08-10	2024-04-29	Sumitomo Pharma Co., Ltd.	Koniugaty przeciwciało-lek zawierające pochodną hemiasterliny
JP7432531B2 (ja) *	2019-02-13	2024-02-16	住友ファーマ株式会社	システイン残基を有するヘミアスタリン誘導体
WO2020166592A1 (ja)	2019-02-13	2020-08-20	大日本住友製薬株式会社	ヘミアスタリン誘導体とその抗体薬物複合体
JP7560255B2 (ja) *	2019-02-13	2024-10-02	住友ファーマ株式会社	ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬
JP7437328B2 (ja) *	2019-02-13	2024-02-22	住友ファーマ株式会社	多能性幹細胞の除去剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2904512A1 (de) *	1979-02-07	1980-08-28	Troponwerke Gmbh & Co Kg	Dehydropeptide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
NZ194747A (en) *	1979-08-29	1988-11-29	Schering Ag	9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives
US4820691A (en)	1987-06-24	1989-04-11	E. R. Squibb & Sons, Inc.	Amino acid 1,2-diketo derivatives as renin inhibitors
US5081225A (en) *	1989-02-09	1992-01-14	E. R. Squibb & Sons, Inc.	Gram-positive and gram-negative antibacterial compounds from the microorganism, janthinobacterium lividum
US5340802A (en) *	1989-06-30	1994-08-23	Abbott Laboratories	Peptide analog type-B CCK receptor ligands
CA2042027A1 (en) *	1989-09-15	1991-03-16	Arthur E. Bogden	Treatment of colon cancer
FR2681075B1 (fr) *	1991-09-05	1994-09-16	Commissariat Energie Atomique	Preparation enzymatique purifiee issue de chromobacterium violaceum, son procede d'obtention et son application a la production d'alpha,beta-dehydrotryptophanyl-peptides.
WO1993017701A1 (en) *	1992-03-12	1993-09-16	The Administrators Of The Tulane Educational Fund	Endothelin receptor-binding peptides
US5721250A (en) *	1993-12-23	1998-02-24	Merck & Co. Inc.	Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5661175A (en) *	1995-06-20	1997-08-26	Kashman; Yoel	Hemiasterlin and geodiamolide TA
US7064211B2 (en) *	2002-03-22	2006-06-20	Eisai Co., Ltd.	Hemiasterlin derivatives and uses thereof

1995
- 1995-04-20 GB GBGB9508195.6A patent/GB9508195D0/en active Pending
1996
- 1996-04-22 CA CA2220021A patent/CA2220021C/en not_active Expired - Lifetime
- 1996-04-22 DK DK96910116T patent/DK0839154T3/da active
- 1996-04-22 AT AT96910116T patent/ATE256698T1/de not_active IP Right Cessation
- 1996-04-22 WO PCT/GB1996/000942 patent/WO1996033211A1/en not_active Ceased
- 1996-04-22 US US08/930,584 patent/US6153590A/en not_active Expired - Lifetime
- 1996-04-22 ES ES96910116T patent/ES2213173T3/es not_active Expired - Lifetime
- 1996-04-22 AU AU53416/96A patent/AU5341696A/en not_active Abandoned
- 1996-04-22 DE DE69631141T patent/DE69631141T2/de not_active Expired - Lifetime
- 1996-04-22 JP JP53156496A patent/JP4008493B2/ja not_active Expired - Lifetime
- 1996-04-22 EP EP96910116A patent/EP0839154B1/de not_active Expired - Lifetime
- 1996-04-22 PT PT96910116T patent/PT839154E/pt unknown
2000
- 2000-06-14 US US09/593,417 patent/US6870028B1/en not_active Expired - Fee Related
2005
- 2005-01-14 US US11/034,922 patent/US7410951B2/en not_active Expired - Fee Related
2006
- 2006-08-14 JP JP2006221150A patent/JP4006466B2/ja not_active Expired - Lifetime
2008
- 2008-07-21 US US12/176,716 patent/US7772397B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7772397B2 (en)	2010-08-10
JP2007031441A (ja)	2007-02-08
PT839154E (pt)	2004-05-31
US20090088573A1 (en)	2009-04-02
JP4006466B2 (ja)	2007-11-14
CA2220021C (en)	2012-06-26
US6870028B1 (en)	2005-03-22
CA2220021A1 (en)	1996-10-24
US7410951B2 (en)	2008-08-12
DK0839154T3 (da)	2004-04-19
EP0839154A1 (de)	1998-05-06
DE69631141T2 (de)	2004-09-30
US6153590A (en)	2000-11-28
JP4008493B2 (ja)	2007-11-14
JPH11505211A (ja)	1999-05-18
EP0839154B1 (de)	2003-12-17
US20050171137A1 (en)	2005-08-04
DE69631141D1 (de)	2004-01-29
ES2213173T3 (es)	2004-08-16
WO1996033211A1 (en)	1996-10-24
GB9508195D0 (en)	1995-06-07
AU5341696A (en)	1996-11-07

Legal Events

Date

Code

Title

Description

2004-09-15

UEP

Publication of translation of european patent specification

Ref document number: 0839154

Country of ref document: EP

2011-01-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE256698T1 (de)	2004-01-15	Biologisch aktive peptide und ihre zubereitungen und verwendungen
CY1107628T1 (el)	2013-04-18	Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
ZA988826B (en)	1999-03-29	Acylsulfamoylbenzamides crop protection compositions comprising them and processes for their preparation
UY24244A1 (es)	2001-10-25	Derivados bicíclicos y policíclicos de isotiazolona
ES2133807T3 (es)	1999-09-16	Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
DE69729877D1 (de)	2004-08-19	Mycophenol bisphosponatverbindungen
BR0116452A (pt)	2003-09-30	Composto, composição farmacêutica, uso de um composto
ATE368054T1 (de)	2007-08-15	Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
CY1108610T1 (el)	2014-04-09	Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DE69724811D1 (de)	2003-10-16	Pentafluorobenzensulfonamide und analoge
ES2181006T3 (es)	2003-02-16	Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion.
TR199903331T2 (xx)	2000-06-21	Farnesil protein transferas engelleyicileri.
PT765152E (pt)	2002-03-28	Estimulacao do crescimento capilar por complexos de peptido-cobre
AU2291097A (en)	1997-10-17	Novel phenanthridines substituted in the 6 position
ATE413179T1 (de)	2008-11-15	Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
TR199800623T2 (xx)	1998-07-21	Yeni amino asit t�revleri, m�stahzarlar� ve kullan�mlar�.
BR0014355A (pt)	2002-07-16	Derivados de sapogenina e seu uso no tratamento de disfunção cognitiva
HUP9800731A2 (hu)	1998-07-28	Eljárás ivarsejt osztódás stimulálására
AR021695A1 (es)	2002-07-31	4,5-pirazinoxindoles, composicion farmaceutica y uso
EP0830456A4 (de)	2001-03-14	ISOLIERTES FrpB NUKLEINSÄUREMOLEKÜL UND ENTSPRECHENDE IMPFSTOFF
DE69825626D1 (de)	2004-09-16	Heterozyklische cytotoxische wirkstoffe
DE69612056D1 (de)	2001-04-19	Terpenderivate (sarcodictyine) als antikrebsmittel
ATE414100T1 (de)	2008-11-15	Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
NZ504614A (en)	2002-12-20	Echinocandin derivatives and application as anti-fungal agents
ATE380821T1 (de)	2007-12-15	Zytotoxische depsipeptide